Is argenx SE (ARGX) a Buy, Sell, or Hold?
NASDAQ : ARGX
argenx SE
$882.56 USD
$10.33 (1.18%)
- Volume
- 221.29K
- Average Volume
- 343.96K
- Market Capitalization
- $54.88B
- P/E Ratio
- 32.19
- Dividend Yield
- 0.00%
- Price Target
- $1050.00
- Year High
- $953.58
- Year Low
- $596.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.12
Company Overview
NASDAQ
Karen Massey
Biotechnology
Healthcare
ARGX
1863
NL
USD
Liquidity Metrics
0.01
5.12
4.89
2.28
0.00
Sales & Valuation
$4.15B
10.65
6.56
49.36
18.00
Profitability
$19.63
$1.29B
32.87%
33.43%
21.66%
16.99%
P/E Metrics
32.19
0.09
0.09
Analyst Price Target & Rating
$1050.00
$1350.00
$932.00
4/5
36 Analysts
-15.95%
Financial Health Scores
20.34
5/9
$6.49B
$10.03B
$1.62B
$2B
Key Metrics (TTM)
$50.86B
9.81
32.03
5.12
21.66%
17.36%
3.13%
2.06%
$288.93
-106 days
Company Executives
| Name | Title |
|---|---|
| Hans de Haard Ir | Co-Founder & Member of Board Advisors |
| Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board |
| Karen Massey | Chief Executive Officer & Executive Director |
| Filip Borgions | Chief Technology Innovation Officer |
| Malini Moorthy | General Counsel & Corporate Secretary |
| Arjen Lemmen | Vice President of Corporate Development & Strategy |
| Karl Gubitz | Chief Financial Officer |
| Andria Wilk | Global Head of Quality |
| Luc Truyen | Chief Medical Officer |
| Peter Ulrichts | Chief Scientific Officer |
| Marc Schorpion | Global Head of Human Resources |
Poll Results
No votes yet today — be the first to share your view!
About argenx SE (NASDAQ:ARGX) Stock
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejectio ... n. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
2026-07-29 10:41:33
Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.
argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
2026-07-28 21:03:42
I upgrade argenx to BUY with a $1,050 price target, citing sustained VYVGART growth, label expansion, and a strong balance sheet. VYVGART's commercial momentum is robust, with expanded indications, at-home administration, and a growing prescriber base supporting long-term growth. Pipeline optionality, notably empasiprubart and autoimmune myositis, provides meaningful upside not fully reflected in ARGX's current valuation.
2026-07-28 14:15:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
2026-07-27 12:27:41
Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
2026-07-27 12:16:37
Global immunology pioneer Argenx SE (NASDAQ:ARGX) on Monday struck a definitive agreement to purchase Forte Biosciences, Inc. (NASDAQ:FBRX) in a substantial all-cash transaction.
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
2026-07-27 10:02:44
argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease.
2026-07-27 02:00:00
argenx (Euronext and Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have e
Frequently Asked Questions
-
What is the current argenx SE (ARGX) stock price?
-
argenx SE(NASDAQ:ARGX) stock price is $882.56 in the last trading session. During the trading session, ARGX stock reached the peak price of $953.58 while $596.01 was the lowest point it dropped to. The percentage change in ARGX stock occurred in the recent session was 1.18% while the dollar amount for the price change in ARGX stock was $10.33.
-
ARGX's industry and sector of operation?
-
The NASDAQ listed ARGX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARGX?
-
Hans de Haard Ir | Co-Founder & Member of Board Advisors
Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board
Karen Massey | Chief Executive Officer & Executive Director
Filip Borgions | Chief Technology Innovation Officer
Malini Moorthy | General Counsel & Corporate Secretary -
How many employees does ARGX have?
-
Number of ARGX employees currently stands at 1863. ARGX operates from Laarderhoogtweg 25, Amsterdam, NH 1101EB, NL.
-
Link for ARGX official website?
-
Official Website of ARGX is: https://www.argenx.com
-
How do I contact ARGX?
-
ARGX could be contacted at phone #31 10 703 8441 and can also be accessed through its website. ARGX operates from Laarderhoogtweg 25, Amsterdam, NH 1101EB, NL.
-
How many shares of ARGX are traded daily?
-
The average number of ARGX shares traded daily for last 3 months was 343.96K.
-
What is the market cap of ARGX currently?
-
The market value of ARGX currently stands at $54.88B with its latest stock price at $882.56